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A B S T R A C T
Objective: To assess the efﬁcacy and safety of a new single-tablet regimen (STR) of tenofovir disoproxil
fumarate (TDF) 300 mg, lamivudine (3TC) 300 mg, and efavirenz (EFV) 600 mg in HIV-infected Thai
patients.
Methods: This was a prospective study performed for 144 weeks among 51 treatment-naïve patients and
49 experienced patients on separate tablets of TDF, 3TC, and EFV with HIV RNA<50 copies/ml. CD4, HIV
RNA, liver and renal function, and lipid proﬁles were assessed at baseline, weeks 12, 24, and 48, and then
every 24 weeks.
Results: The median baseline CD4 cell count was 512 cells/ml for treatment-experienced patients and
230 cells/ml for treatment-naïve patients. Median baseline log10 HIV-1 RNA for treatment-naïve subjects
was 4.9 copies/ml. From the intention-to-treat (ITT) analysis, the proportion of subjects with HIV RNA
<50 copies/ml at week 48, 96, and 144 was 95%, 94%, and 94%, respectively, for antiretroviral-experienced
patients and 88%, 90%, and 80%, respectively, for antiretroviral-naïve patients. One virological failure at
week 12 had primary drug resistance of K70R, T69D, V75L. Three serious adverse events occurred
(tension headache, infective endocarditis, and cervical dysplasia) and another three discontinued the
study drug due to EFV intolerance.
Conclusions: This generic STR TDF/3TC/EFV is effective and well-tolerated. These ﬁndings lend support to
the use of this generic STR as ﬁrst-line antiretroviral therapy in resource-limited settings.
© 2017 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
Introduction
Since it is currently not possible to completely eradicate HIV,
the long-term use of combination antiretroviral therapy (cART) is
necessary for life-long viral suppression and to prevent HIV disease
progression. Therefore, a potent, non-toxic, and easy to take ﬁrst-
line antiretroviral therapy (ART) regimen is particularly important.
Although most international treatment guidelines for HIV infec-
tion recommend the use of tenofovir disoproxil fumarate (TDF)/
emtricitabine (FTC) or tenofovir alafenamide (TAF)/FTC plus an
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integrase inhibitor, recent World Health Organization (WHO)
guidelines from 2016 continue to recommend TDF/FTC or TDF +
lamivudine (3TC) + efavirenz (EFV) once daily as the preferred
ﬁrst-line regimen for resource-limited settings (WHO, 2017;
European AIDS Clinical Society (EACS), 2017; Department of
Health and Human Services (DHHS), 2017; Gunthard et al., 2016). A
previous study showed that a once-daily regimen of TDF, 3TC, and
EFV (administered as individual agents) was superior to once-daily
EFV in combination with 3TC/AZT (Arrizabalaga et al., 2007;
Bartlett et al., 2007; Matthews et al., 2008), 3TC/stavudine (d4T)
(Gallant et al., 2004), or 3TC/abacavir administered twice daily
(Condoluci et al., 2008). The successful long-term treatment of
HIV/AIDS requires exceptionally high levels of adherence to
prevent the emergence of drug-resistant HIV variants, which
can result in treatment failure and the risk for AIDS progression. To
achieve plasma HIV RNA of <50 copies/ml, the most convenient
regimen with the lowest number of pills taken once daily is
preferred.
The availability of cheap antiretroviral (ARV) drugs is essential
for treatment scale-up and to maintain the sustainability of
national HIV programs in resource-limited settings that have been
hard hit by the HIV/AIDS epidemic, such as Thailand. Generic ARV
drugs are generally 3–10 times cheaper than branded products and
are therefore increasingly used in resource-limited settings. The
generic single-tablet regimen (STR) is a signiﬁcant innovation, as it
reduces the number of pills taken each day. In addition, ﬁxed-dose
combinations (FDCs) are easier to manage for both patients and
healthcare workers. Therefore, a generic STR of d4T (or zidovu-
dine), 3TC, and nevirapine (NVP) has been used widely in the
developing world. However, in 2010, the WHO recommended that
countries phase out the use of d4T due to its serious side effects.
In 2009, Mylan Laboratories in India ﬁled an application for a
new drug approval with the US Food and Drug Administration for a
generic STR of TDF/3TC/EFV at 600/300/300 mg. Based on a
bioequivalence study in India, this generic FDC yielded comparable
bioequivalence data to the branded individual EFV, 3TC, and TDF
(unpublished data). However, there are no efﬁcacy and safety data
in HIV-infected subjects. This generic STR will give patients the
opportunity to access an ‘ease-of-use’ product not currently
available on the market, as well as help improve their quality of life
and adherence. In addition, there are limited data on the use of the
generic TDF/3TC/EFV worldwide. Therefore, this study was
performed to assess the long-term safety and efﬁcacy of a STR
of TDF/3TC/EFV over a period of 144 weeks. Mid-level concen-
trations of TDF, 3TC, and EFV were evaluated to ensure that this
generic STR was identical to separate tablets of branded TDF and
EFV.
Materials and methods
This open-label, phase II trial was conducted at HIV-NAT, Thai
Red Cross AIDS Research Centre (TRC-ARC), Bangkok, Thailand,
from May 2010 to June 2015 (registered at clinicaltrials.gov,
NCT01160120). Treatment-experienced and treatment-naïve
patients older than 18 years of age with no concurrent AIDS-
deﬁning illness or history of drug resistance, with an estimated
glomerular ﬁltration rate (eGFR) of >60 ml/min/1.73 m2, and with
no history of drug abuse or of taking CYP450 inhibitors or inducers
within 14 days of the study were recruited. Additional inclusion
criteria for treatment-experienced patients were (1) currently
using individual TDF, 3TC, and EFV (as separate tablets) as their
ﬁrst-line regimen, and (2) an HIV RNA of <50 copies/ml for the last
6 months. The treatment-experienced group took branded TDF,
branded EFV, and generic 3TC (from the Government Pharmaceu-
tical Organization (GPO)) up until the baseline visit.
This study was approved by the Ethics Committee, Faculty of
Medicine, Chulalongkorn University. All patients provided their
consent.
Pharmacokinetic analysis
Blood from treatment-experienced and treatment-naïve
patients was collected 11–13 h after the last drug administration
on the fourth week of the study to assess the mid-dose (C12) levels
Figure 1. Study ﬂow diagram.
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of tenofovir, 3TC, and EFV. For the treatment-experienced patients,
blood was also taken at baseline (when the patients were on
individual branded TDF and EFV as separate tablets) 11–13 h after
the last drug administration for comparison with the drug levels of
the generic single FDC at week 4. Plasma concentrations of
individual medications were determined using a previously
developed and validated reverse-phase high-performance liquid
chromatography (HPLC) assay (Droste et al., 2005; Fletcher and
Bushman, 2003). The 3TC plasma levels were tested at the Program
for Health: Prevention and Treatment (PHPT) Research Unit,
Chiang Mai. The tenofovir and EFV plasma levels were tested at the
HIV-NAT Research Laboratory, TRC-ARC, Thailand. Plasma levels of
tenofovir, 3TC, and EFV were linear over the range of 0.015–1.5 mg/
l, 0.028–10.9 mg/l, and 0.2–20.0 mg/l, respectively. The PHPT
Research Unit and HIV-NAT laboratory participate in the Interna-
tional Quality Control and Quality Assessment Program and have
been cross-validated with other PK laboratories (Droste et al.,
2003).
All other laboratory tests were done at the HIV-NAT Laboratory,
Chulalongkorn University Hospital. HIV-RNA viral load, CD4 cell
counts, and various other safety parameters including complete
blood count, blood chemistry, and liver and renal function, were
performed at baseline and at weeks 4, 12, 24, 48, 96, and 144. eGFR
was calculated using the Modiﬁcation of Diet in Renal Disease
(MDRD) formula for the Thai population (eGFR = 175  CrEnz(1.154)
 Age(0.203) 0.742 (if female)  1.129) (Praditpornsilpa et al.,
2011).
The primary outcome of the study was the comparison of drug
levels between formulations and bioequivalence of each composite
drug with a 90% conﬁdence interval (CI) within 0.80–1.25. The
secondary endpoints were the percentages of patients with
undetectable HIV-RNA (<50 copies/ml) and CD4 changes at weeks
48, 96, and 144.
Statistical analysis
In general, all subjects enrolled in the trial were included in the
statistical evaluation for safety and efﬁcacy. Of all subjects
included, one was excluded from the statistical analysis for
pharmacokinetics because baseline data were not obtained due to
problems in collecting blood. Demographic, clinical, and laboratory
parameters were recorded for the patients. Continuous variables
are expressed as the median with interquartile range (IQR).
Differences in continuous and categorical variables between the
experienced and naïve groups were assessed using the Wilcoxon
rank sum test and Chi-square test, respectively. All p-values
reported are two-sided. Statistical signiﬁcance was deﬁned as
p < 0.05. Stata version 13.1 (Stata Corp., College Station, TX, USA)
was used for the analysis.
Results
The study scheme is presented in Figure 1. Of the total 100
patients enrolled, 30% were female and the median age was 34 (IQR
28–38) years. Fifty-one patients were treatment-naïve. The
median baseline CD4 cell count was 512 (IQR 395–620) cells/ml
for treatment-experienced patients and 230 (IQR 156–284) cells/
ml for treatment-naïve patients. The median baseline log10 HIV-1
RNA for treatment-naïve subjects was 4.9 (IQR 4.2–5.3) copies/ml.
Nineteen percent of the subjects were also co-infected with
hepatitis B virus and 3% were co-infected with hepatitis C virus.
The baseline characteristics of the treatment-experienced and
treatment-naïve patients are summarized in Table 1.
Virological and immunological response
At baseline, there were 27 treatment-naïve patients with a
CD4 count <250 cells/ml (range 10–244 cells/ml). Of these
27 patients, 10 continued to have a CD4 <250 cells/ml at week
24 and six continued to have a CD4 <250 cells/ml at week 48. The
median CD4 count for the treatment-naïve patients at weeks 24
and 48 were 364 (IQR 262–452) and 400 (IQR 325–505) cells/ml,
respectively. Changes in the absolute CD4 cell count and
CD4 percentage are summarized in Figure 2A and Table 2.
From the intention-to-treat (ITT) analysis, the proportion of
cases with HIV RNA <50 copies/ml at week 48, 96, and 144 was
96%, 94%, and 94%, respectively, for ARV-experienced patients and
88%, 90%, and 80%, respectively, for ARV-naïve patients. From the
per-protocol (PP) analysis, the proportion of cases with HIV RNA
<50 copies/ml at week 48, 96, and 144 was 98%, 100% and 100%,
respectively, for ARV-experienced patients and 88%, 94%, and 91%,
respectively, for ARV-naïve patients (Figure 2B). One naïve patient
had virological failure at week 12 with baseline primary drug
resistance of K70R, T69D, V75L.
Pharmacokinetic data (Figure 3)
At week 4 (n = 100), the median C12 for tenofovir, 3TC, and EFV
was 0.084 (IQR 0.066–0.1) mg/l, 0.224 (IQR 0.17–0.3) mg/l, and 1.88
(IQR 1.44–2.73) mg/l, respectively. Therapeutic cut-off levels for
3TC, TDF, and EFV of >0.05 mg/l, >0.05 mg/l, and > 1.0 mg/l,
respectively, were used.
Among the treatment-experienced patients, the geometric
mean ratio (GMR) of the tenofovir plasma concentration at week 4
(single generic FDC) over baseline (branded TDF) was 0.98 (95% CI
0.94–1.04). There was only one patient outlier (1.52). At week 4,
this patient had a tenofovir (generic) level of 0.102 mg/l. The GMR
of 3TC levels at week 4 over baseline (generic 3TC) was 1.14 (95% CI
1.02–1.28). With regard to the EFV levels, the GMR at week 4 of
Table 1
Baseline characteristics of the 100 study patients.a
Variables Total Treatment-experienced patients (n = 49) Treatment-naïve patients (n = 51) p-Value
Age (years) 34.5 (28.5–39) 38 (35–45) 30 (25–35) <0.01
Sex: male 70 (70) 27(55.1) 43(84.3) <0.01
HIV transmission risk <0.01
Heterosexual 43 (43) 31 (63.3) 12 (23.5)
Homosexual 56 (56) 17 (34.7) 39 (76.5)
HBV co-infection 19 (19) 16 (32.7) 3 (5.9) <0.01
HCV co-infection 3 (3) 2 (4.1) 1 (2) 0.61
BMI (kg/m2) 21.9 (20.1–23.8) 22.6 (20.9–24.5) 21 (19.4–23.3) 0.01
Duration on ARV for the experienced group, years – 8.9 (6.3–13.2) –
CD4 cell count, cells/ml 512 (395–620) 230 (156–284)
HIV RNA log10 copies/ml <50 4.9 (4.2–5.3)
HBV, hepatitis B virus; HCV, hepatitis C virus; BMI, body mass index; ARV, antiretroviral.
a Data represent the number (%) or median (interquartile range).
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generic EFV over branded EFV was 0.86 (95% CI 0.79–0.93). All drug
concentrations for the generic STR were within 80–120% of the
branded separate tablets and thus interpreted as bioequivalent.
Safety proﬁle (Figure 4)
There were no signiﬁcant changes in the eGFR between the
baseline visit and follow-up visits (Figure 4A). However, one
treatment-experienced patient had subclinical deterioration of the
eGFR which was <60 ml/min/1.73 m2 at weeks 24 and 48 (58 and
50 ml/min/1.73 m2, respectively). Also, there were no signiﬁcant
differences in the lipid proﬁle between the baseline visit and
follow-up visits (Figure 4B). High cholesterol and triglyceride were
observed in 30–50%.
Three serious adverse events were reported during the study
period: tension headache, cervical dysplasia, and infective
endocarditis. The tension headache occurred 1.5 months after
taking generic TDF/3TC/EFV and resolved spontaneously within 1
month. The case of cervical dysplasia was reported when the
affected patient was hospitalized for a hysterectomy, which was
performed 6 months after the baseline visit. The case of infective
endocarditis (Enterococcus faecalis) was diagnosed 6 months after
the baseline visit; this patient was treated in the hospital for 6
weeks and made a full recovery.
Seventy-seven possible study drug-related adverse events were
reported. The most common adverse events were central nervous
system (CNS) toxicity (dizziness (28%) and short-term memory
loss (4%)) and skin rash (10%). The majority of the CNS adverse
events occurred during the ﬁrst few days of treatment and resolved
spontaneously after 1–4 weeks. However, three patients discon-
tinued the study drug due to EFV intolerance. Another three cases
were pregnant. They had healthy newborns without congenital
anomalies.
Discussion
In order to achieve the 90–90–90 target by 2030, ART scale-up is
essential. However, this will be difﬁcult because treatment for
HIV-infected patients is life-long. Therefore, it is crucial to make
the drugs accessible, affordable, efﬁcacious, and easy to take,
which is the case for generic STRs. In the present study, the plasma
drug concentrations and efﬁcacy over a period of 144 weeks of a
generic STR including TDF/3TC/EFV (one tablet a day) was
investigated. The pharmacokinetic data conﬁrm that this generic
FDC has comparable plasma concentrations to the separate tablets.
Drug concentrations below the target cut-off values at the time of
generic STR use were found in only four patients for TDF, two
patients for 3TC, and three patients for EFV. However, all of them
had HIV RNA <50 copies/ml over the 144 weeks. Excellent
virological efﬁcacy over the 144 weeks was also found for both ARV
treatment-naïve patients with high baseline viral loads and
treatment-experienced patients with undetectable viral loads,
especially in patients with high levels of adherence and no primary
drug resistance.
This one tablet a day regimen was associated with high levels of
adherence and with minimal treatment-limiting toxicity. None of
these patients developed grade 3/4 renal toxicity, in contrast to the
ﬁndings of a study from West India (Pujari et al., 2008). Pujari et al.
found that 2.8% of their HIV-infected patients from West India
developed grade 3/4 renal toxicity when taking a generic STR of
TDF/FTC/EFV. The present study patients were younger (mean age
32 years compared to 40 years) and none of them had co-
morbidities, so the TDF-related nephrotoxicity was relatively low
in this study population.
Figure 2. (A) CD4 cell counts over the 144-week study period. (B) Proportion of
patients with HIV-1 RNA <50 copies/ml at weeks 48, 96, and 144.
Table 2
Virological success and median CD4 cell counts during the study (by on-treatment analysis).
Overall Experienced Naïve p-Value
CD4 (cells/ml), median (IQR)
Week 24 433 (331–564) 563 (420–750) 364 (262–452) <0.001
Week 48 475 (351–598) 550 (434–739) 400 (325–505) <0.001
Week 72 502 (378–637) 590 (473–774) 431 (336–548) <0.001
Week 96 510 (403–641) 527 (451–736) 495 (363–586) 0.02
Week 120 486 (408–656) 564 (416–702) 461 (396–532) 0.02
Week 144 526 (432–650) 582 (459–744) 489 (371–603) 0.01
HIV RNA <50 copies/ml, n/N (%)
Week 24 92/99 (92.9) 48/48 (100) 44/51 (86.3) 0.01
Week 48 92/99 (92.9) 47/48 (97.9) 45/51 (88.2) 0.06
Week 72 93/97 (95.9) 46/46 (100) 47/51 (92.2) 0.05
Week 96 92/96 (95.8) 46/47 (97.9) 46/49 (93.9) 0.33
Week 120 83/88 (94.3) 45/45 (100) 38/43 (88.4) 0.02
Week 144 87/91 (95.6) 46/46 (100) 41/45 (91.1) 0.03
IQR, interquartile range.
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The high efﬁcacy of the generic STR of TDF/3TC/EFV at week 144
in this study (94% of ARV-experienced patients and 80% of ARV-
naïve patients) is comparable to the data reported for the branded
FDC of EFV, FTC, and TDF as the ﬁrst-line or switched highly active
ART regimen among patients with similar baseline HIV disease
status in developed countries (Dejesus et al., 2009; Gallant et al.,
2006; Omeje and Okwundu, 2012). Furthermore, the virological
efﬁcacy recorded in this study is far superior to that reported in
other ARV studies conducted in Thailand in which a STR of d4T or
zidovudine (AZT)/3TC/NVP was used (Anekthananon et al., 2004;
Manosuthi et al., 2007; van Leth et al., 2004). Although the generic
STR of d4T or AZT with 3TC and NVP is effective in achieving
virological, immunological, and clinical success in the developing
world (Anekthananon et al., 2004; Kiertiburanakul et al., 2007;
Laurent et al., 2007; Laurent et al., 2004; Pujari et al., 2004), the
serious side effects of d4T are of concern. Therefore, the use of a
non-thymidine analog such as TDF is preferred instead. Further-
more, in 2010, the WHO recommended that countries phase out
the use of d4T due to its serious side effects.
There are several advantages to starting with TDF-based ART for
the treatment of HIV infection. In randomized clinical trials, a
combination of TDF/3TC (FTC)/EFV was superior to AZT or d4T/3TC/
EFV, with better virological and immunological outcomes and less
treatment-limiting toxicity in the TDF group (Gallant et al., 2004;
Pozniak et al., 2006). In addition, a systematic review of clinical
trials demonstrated that TDF/FTC or TDF/3TC combined with EFV
achieves a greater virological response than other nucleoside
backbones (Bartlett et al., 2007). In the present study, the patients
showed a robust immunological and virological response, with
>90% of them having a viral load <50 copies/ml over the
144 weeks.
This generic STR of TDF/3TC/EFV has numerous advantages,
such as a low pill burden (only one tablet a day), being cheaper
than the generic STR of TDF/FTC/EFV or separate drugs, fewer
prescription errors, simpliﬁed HIV program management, and
improved effectiveness in treating concomitant chronic hepatitis B
virus infection. Chronic hepatitis B virus co-infection in the Asia
region is relatively high due to perinatal transmission; 19% of the
patients in this study were found to have a concomitant chronic
hepatitis B virus infection. However, its disadvantage is the
difﬁculty in adjusting the dose in cases with a low eGFR or TDF-
related renal toxicity.
Generic ART will play a critical role in HIV treatment scale-up in
many resource-limited settings, especially during and after
international funding donors phase out their programs. In the
near future, more HIV-infected patients in resource-poor settings
will engage in HIV treatment programs, because early ART is
recommended in the international guidelines (WHO, 2017;
European AIDS Clinical Society (EACS), 2017; Department of
Health and Human Services (DHHS), 2017; Gunthard et al., 2016).
Furthermore, treatment as a prevention strategy is also recom-
mended, especially in special populations such as men who have
sex with men. Therefore, generic drugs may be a good alternative
option in resource-limited settings, particularly generic STRs,
Figure 3. Fraction distribution plots of tenofovir disoproxil fumarate (TDF), lamivudine (3TC), and efavirenz (EFV) at week 4 (generic single-tablet regimen) compared to
baseline levels (individual tablets); mean and 95% CI.
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which carry a lower cost, have high efﬁcacy, little toxicity, and the
least number of pills taken once daily to improve adherence. Hence
one tablet of the generic STR TDF/3TC/EFV would be a good choice
for the successful long-term treatment of HIV/AIDS worldwide. It
will help delay the need for second-line therapy, which is more
expensive, as well as make the ART program more feasible and
sustainable in the long run.
Presently, integrase inhibitor-based regimens are the preferred
ART in many resource-rich countries (European AIDS Clinical
Society (EACS), 2017; Department of Health and Human Services
(DHHS), 2017; Gunthard et al., 2016). Dolutegravir is of particular
interest to resource-limited settings because it is well tolerated,
taken once a day, and has a higher barrier to resistance. The result
of the SINGLE randomized clinical trial indicated that dolutegravir
plus abacavir (ABC)–3TC maintained superiority over TDF/FTC/EFV
through 144 weeks in previously untreated HIV-infected patients:
71% on dolutegravir/ABC/3TC vs. 63% on EFV/TDF/FTC had a viral
load <50 copies/ml (Walmsley et al., 2015). Additionally, ViiV
Healthcare extended their Medicines Patent Pool license agree-
ment for dolutegravir to cover all lower middle-income countries.
Unfortunately, Thailand is excluded from this program. The cost of
dolutegravir in Thailand is still expensive at 285 USD per month.
Therefore, dolutegravir cannot be the preferred ﬁrst-line ART in the
HIV program in Thailand at the present time. It is hoped that the
Figure 4. Change in (A) eGFR, and (B) cholesterol, triglyceride, LDL, and HDL.
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generic STR of dolutegravir/3TC (FTC)/TAF will become available
soon. This regimen would be a promising ﬁrst-line ART in resource-
limited settings with high levels of hepatitis B virus co-infection.
This study has some limitations. First, due to budget
constraints, the study had only one arm, which means that it is
not as powerful as a double-blind randomized controlled trial.
Second, the sample size was relatively small and the duration of
follow-up was relatively short. Long-term follow-up of this generic
STR is warranted to evaluate the long-term efﬁcacy and toxicity.
However, the results of this study will have a major impact on the
scale-up of ﬁrst-line therapy and will result in improved access to
therapy nationwide. Third, the separate 3TC tablet used was also a
generic drug from the Thai GPO. Branded 3TC could not be used in
this study because of its cost. Finally, the low EFV-related CNS
toxicity may in part be because 50% of patients already tolerated
EFV prior to taking the generic STR used. Additionally, the low TDF
renal toxicity is mainly due to younger age and less co-morbidity,
and 76% of them were homosexual males. Therefore, the results of
this study may not be generalizable to an older and female
population.
In conclusion, although this study was not a randomized clinical
trial, it does demonstrate that the use of a generic STR of TDF/3TC/
EFV is safe and highly effective as a ﬁrst-line non-nucleoside
reverse-transcriptase inhibitor (NNRTI) regimen. Comparative
randomized controlled trials with a larger sample size and a
longer follow-up period of more than 144 weeks are required to
show that this generic STR is superior to other regimens. The
results from this study support the use of a generic STR of TDF/3TC/
EFV as the ﬁrst-line ART in resource-limited settings, and this
generic drug could help us to achieve the UNAIDS goal by 2030.
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